1 citations
,
April 2022 in “F1000Research” This study found that pediatric cancer patients at Muhimbili National Hospital commonly experienced adverse drug reactions during chemotherapy, despite drug prescribing patterns aligning with essential medicine lists.
May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
January 2024 in “Faculty of 1000 Research Ltd” In this study, researchers at Muhimbili National Hospital observed that pediatric cancer patients undergoing chemotherapy frequently experienced adverse drug reactions, such as nausea and vomiting, hair loss, and neutropenia, despite drug prescribing patterns aligning with the essential medicine list.
July 2026 in “Dermatology Practical & Conceptual” This narrative review reports that IL-17 and IL-23 inhibitors, while effective for psoriasis and other inflammatory diseases, can cause a variety of skin reactions that resemble primary dermatoses, highlighting the need for careful diagnosis and varied management strategies.
97 citations
,
May 2008 in “Journal of Cutaneous Pathology” This review highlights the challenges in identifying histological features of adverse reactions to soft tissue fillers and emphasizes the need for increased awareness due to product uncertainty and delayed reactions.